Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled "Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis" was published in the peer-reviewed journal Frontiers in Veterinary Science and is available online.

The study described in the publication demonstrated that oral treatment with Piclidenoson resulted in statistically significant improvement in mobility and pain assessments in dogs suffering from osteoarthritis, while maintaining a favorable safety profile. The study supports the continued development of Piclidenoson as a potential oral disease-modifying therapy for canine osteoarthritis.